EGFR and melanoma: Patients with brain metastases from melanoma, breast cancer, certain genotypes of non-small cell lung cancer (NSCLC; e.g., EGFR-activating mutations, ALK translocations), and renal cell carcinoma benefit most from a multidisciplinary approach.